Organization
AIM Vaccine
13 clinical trials
Clinical trial
A Single-center, Randomized, Blinded, Placebo-controlled Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of One Dose of the SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in People Aged 18 Years and Older Who Had Received Two or Three Doses of Inactivated COVID-19 VaccineStatus: Recruiting, Estimated PCD: 2023-09-01
Clinical trial
Phase Ⅱ Clinical Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) in Chinese People Aged 18~59 YearsStatus: Completed, Estimated PCD: 2022-06-23
Clinical trial
A Cohort Study to Evaluate Safety and Immunogenicity of COVID-19 mRNA Vaccine, Bivalent (LVRNA021) in Participants Aged 18 Years and Over in ChinaStatus: Active (not recruiting), Estimated PCD: 2022-12-23
Clinical trial
A Preliminary Exploratory Cohort Study to Evaluate Safety, Tolerability and Immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in Participants Aged 18 Years and Over in ChinaStatus: Active (not recruiting), Estimated PCD: 2022-12-19
Clinical trial
A Multi-center, Randomized, Blinded, Placebo-controlled, Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) as Booster in Participants Aged 18 Years and Older Who Completed Primary/1 Booster Dose(s) of SARS-CoV-2 VaccinationStatus: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
A Cohort Study to Evaluate Safety and Immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in Participants Aged 18 Years and Over in ChinaStatus: Not yet recruiting, Estimated PCD: 2023-04-01
Clinical trial
Randomized, Blinded, Positive and Placebo-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) Booster Vaccination in People 18 Years of Age and Older Who Have Received SARS-CoV-2 Vaccine.Status: Active (not recruiting), Estimated PCD: 2023-11-30
Clinical trial
A Preliminary Exploratory Cohort Study to Evaluate Safety, Tolerability and Immunogenicity of COVID-19 mRNA Vaccine, Bivalent (LVRNA021) in Participants Aged 18 Years and Over in ChinaStatus: Active (not recruiting), Estimated PCD: 2022-12-05
Clinical trial
Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) in Chinese People Aged 18 Years and OverStatus: Active (not recruiting), Estimated PCD: 2022-10-14
Clinical trial
A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19 in Participants Aged 18 Years and OlderStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
An Open-Label, Phase 1 Clinical Study to Determine the Safety and Preliminary Immunogenicity of SARS-CoV-2 Variant mRNA Vaccine (LVRNA010) in Healthy Participants Aged 18 Years and OlderStatus: Not yet recruiting, Estimated PCD: 2023-05-01
Clinical trial
A Randomized, Blinded, Parallel-controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of SARS-CoV-2 mRNA Vaccine (LVRNA009) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated 2 Doses Inactivated SARS-CoV-2 VaccineStatus: Not yet recruiting, Estimated PCD: 2023-10-01
Clinical trial
Randomized, Blinded, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) in Participants Aged 18 Years and Older Who Have Received SARS-CoV-2 VaccineStatus: Active (not recruiting), Estimated PCD: 2023-09-28